Takeaways: Health Canada’s authorization of the XFG‑adapted Comirnaty vaccine for the 2026–2027 season keeps Pfizer/BioNTech aligned with national recommendations to match contemporary Omicron l...
Takeaways: Roche’s dual-formulation (IV and SC) authorization for Lunsumio (mosunetuzumab) in Canada creates flexible, fixed-duration access for relapsed/refractory follicular lymphoma...
Takeaways: Novo Nordisk’s updated Rybelsus in Canada is a smaller-tablet, lower-milligram GLP-1 formulation that delivers the same clinical effect as the original 3/7/14 mg doses, with 1.5/4/9 m...
